{"url_path":"/sec/aqst/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000029-index.html","accession_number":"0001398733-26-000029","cik":"0001398733","ticker":"AQST","issuer_name":"Aquestive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1398733/0001398733-26-000029-index.html","primary_entity_key":"0001398733","primary_entity_name":"Aquestive Therapeutics, Inc."},"word_count":128,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit NumberDescription\n\n[99.1](q12026-ex991earningsrelease.htm)\nPress Release, dated May 13, 2026, announcing the Company’s reported financial results for the first quarter ended March 31, 2026 and providing an update on recent developments in its business.\n\n[99.2](debtrefinancepressreleas.htm)\nAquestive Therapeutics, Inc. press release dated May 12, 2026.\n\n[99.3](earningsreleasesupplemen.htm)\nAquestive Therapeutics, Inc. Q1 Earnings Supplemental Materials dated May 13, 2026.\n\n104Cover Page Interaction Data File (embedded within the Inline XBRL document)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: May 13, 2026\nAquestive Therapeutics, Inc.\n\n   \n\n By:/s/ A. Ernest Toth, Jr\n\n  Name: A. Ernest Toth, Jr.\n\n  Title: Chief Financial Officer"}